The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Studies of Murine Schistosomiasis Reveal Interleukin–13 Blockade As A Treatment for Established and Progressive Liver Fibrosis
Open accessAbstract
In several allergic, autoimmune, and infectious diseases, fibrosis is a major cause of morbidity and mortality. Here, using a model of infection–induced liver fibrosis, we show that interleukin (IL)–13 is required at all stages of Schistosomiasis mansoni infection to induce fibrosis. IL–4 production was preserved in IL–13-deficient mice, yet failed to significantly contribute to the fibrotic response in either acute or chronic infection. Significant fibrosis develops in all infected mice, although the magnitude of the response varies widely in inbred mice. C3H/HeN, BALB/c, and C57BL/6 mice develop high, intermediate, and low levels of fibrosis, respectively. Despite these differences, IL–13 antagonism resulted in a marked amelioration of fibrosis in all strains. The fibrotic mechanism in the high– and low–responder strains was unrelated to their tissue eosinophil or mast cell responses, but did correlate with their patterns of IL–13, IL–10, and interferon gamma (IFN–γ) mRNA expression. Indeed, severe fibrosis correlated with a high IL–13 and low IFN–γ/IL–10 mRNA response. Because fibrotic diseases are typically progressive disorders, an important issue was to determine whether IL–13 inactivation might be used to treat an established and ongoing fibrotic disease. Here, IL–13 antagonism was highly efficacious, even after fibrosis and the Th2 cytokine response were firmly established. These studies demonstrate the central role played by IL–13 in fibrogenesis and suggest that therapeutic approaches aimed at disrupting the IL–13 pathway will be highly effective at preventing fibrotic disease caused by chronic Th2–mediated inflammatory reactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chiaramonte, M. G., Donaldson, D. D., Cheever, A. W., & Wynn, T. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7325 · Cited by 603
Self-citationAlcoholic liver disease: New insights in pathogenesis lead to new treatments
Lieber, C. S. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80420-1 · Cited by 260
Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts
Oriente, A., Fedarko, N. S., Pacocha, S. E., Huang, S.-K., Lichtenstein, L. M., & Essayan, D. M. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35380-7 · Cited by 230
Cited by
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Self-citationFibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765
Self-citationCommon and unique mechanisms regulate fibrosis in various fibroproliferative diseases
Wynn, T. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31487 · Cited by 1,456
Self-citationMacrophages: master regulators of inflammation and fibrosis
Wynn, T., & Barron, L. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255354 · Cited by 1,392
Self-citationWynn, T. A. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141142 · Cited by 958
Self-citation
Metadata
- Authors
- Chiaramonte, M. G., Cheever, A. W., Malley, J. D., Donaldson, D. D., & Wynn, T. A.
- Venue
- Hepatology
- Published
- 2001-08
- Volume
- 34
- Issue
- 2
- Pages
- 273-282
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2081802477
- Cited by
- 174
- References
- 3
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Studies of Murine Schistosomiasis Reveal Interleukin–13 Blockade As A Treatment for Established and Progressive Liver Fibrosis. https://app.cochat.ai/papers/10.1053/jhep.2001.26376
- The paper
- Chiaramonte, M. G., Cheever, A. W., Malley, J. D., Donaldson, D. D., & Wynn, T. A. (2001). Studies of Murine Schistosomiasis Reveal Interleukin–13 Blockade As A Treatment for Established and Progressive Liver Fibrosis. Hepatology. https://doi.org/10.1053/jhep.2001.26376
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.